Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2002 Nov;73(5):500–507. doi: 10.1136/jnnp.73.5.500

Goal setting and attainment in Alzheimer's disease patients treated with donepezil

K Rockwood 1, J Graham 1, S Fay 1
PMCID: PMC1738123  PMID: 12397141

Abstract

Objectives: To understand the treatment goals of Alzheimer's disease (AD) patients, carers, and physicians; to estimate whether clinically important goals are met during treatment with donepezil; and to compare a measure of goal attainment with standard measures used to evaluate AD treatment.

Methods: In a 12 month phase IV trial, 108 patients with mild to moderate AD, their primary carers, and treating physicians set goals assigned to five domains, using Goal Attainment Scaling (GAS) as the primary outcome. Goal attainment was assessed quarterly. GAS scores were correlated with standard outcomes, including the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog), and the Clinician's Interview-Based Impression of Change-Plus (CIBIC-plus).

Results: Physicians set fewer goals (342, mean (SD) per patient=3 (1)) than patients/carers (855, mean=9 (3)), particularly in leisure (20% by physicians compared with 76% by patients/carers), and social interaction (24% versus 49%). Physicians observed statistically significant improvement in global goal attainment for six months, and patients/carers for nine months. Patients/carers described consistent goal attainment, whereas physicians observed variable effects, such as decline in cognition but improved social interaction and behaviour. Physician global GAS scores correlated highly with the CIBIC-plus at weeks 12 (r= -0.82) and 52 (r=-0.80), but not with the ADAS-cog (r=0.12 and r=-0.45, respectively). Patient/carer global GAS scores correlated moderately with the physician's CIBIC-plus (week 12 r=-0.51; week 52 r=-0.56), and nominally with the ADAS-cog.

Conclusions: Patients/carers and physicians differ in their expectations and impressions of treatment effects. Clinically important changes correlated only modestly with psychometric tests. Attainment of treatment goals does not accord with a simplistic model in which successful AD treatment means that all declines uniformly improve.

Full Text

The Full Text of this article is available as a PDF (196.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexopoulos G. S., Abrams R. C., Young R. C., Shamoian C. A. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988 Feb 1;23(3):271–284. doi: 10.1016/0006-3223(88)90038-8. [DOI] [PubMed] [Google Scholar]
  2. Bogardus S. T., Jr, Bradley E. H., Tinetti M. E. A taxonomy for goal setting in the care of persons with dementia. J Gen Intern Med. 1998 Oct;13(10):675–680. doi: 10.1046/j.1525-1497.1998.00203.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burns A., Rossor M., Hecker J., Gauthier S., Petit H., Möller H. J., Rogers S. L., Friedhoff L. T. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord. 1999 May-Jun;10(3):237–244. doi: 10.1159/000017126. [DOI] [PubMed] [Google Scholar]
  4. Davis K. L., Mohs R. C., Marin D., Purohit D. P., Perl D. P., Lantz M., Austin G., Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999 Apr 21;281(15):1401–1406. doi: 10.1001/jama.281.15.1401. [DOI] [PubMed] [Google Scholar]
  5. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  6. Francis P. T., Palmer A. M., Snape M., Wilcock G. K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137–147. doi: 10.1136/jnnp.66.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gordon J. E., Powell C., Rockwood K. Goal attainment scaling as a measure of clinically important change in nursing-home patients. Age Ageing. 1999 May;28(3):275–281. doi: 10.1093/ageing/28.3.275. [DOI] [PubMed] [Google Scholar]
  8. Greenberg S. M., Tennis M. K., Brown L. B., Gomez-Isla T., Hayden D. L., Schoenfeld D. A., Walsh K. L., Corwin C., Daffner K. R., Friedman P. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol. 2000 Jan;57(1):94–99. doi: 10.1001/archneur.57.1.94. [DOI] [PubMed] [Google Scholar]
  9. Joffres C., Graham J., Rockwood K. Qualitative analysis of the clinician interview-based impression of change (Plus): methodological issues and implications for clinical research. Int Psychogeriatr. 2000 Sep;12(3):403–413. doi: 10.1017/s1041610200006505. [DOI] [PubMed] [Google Scholar]
  10. Joyce B. M., Rockwood K. J., Mate-Kole C. C. Use of goal attainment scaling in brain injury in a rehabilitation hospital. Am J Phys Med Rehabil. 1994 Feb;73(1):10–14. [PubMed] [Google Scholar]
  11. Knopman D. S., Knapp M. J., Gracon S. I., Davis C. S. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology. 1994 Dec;44(12):2315–2321. doi: 10.1212/wnl.44.12.2315. [DOI] [PubMed] [Google Scholar]
  12. Lawton M. P., Brody E. M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969 Autumn;9(3):179–186. [PubMed] [Google Scholar]
  13. Lyness J. M., Noel T. K., Cox C., King D. A., Conwell Y., Caine E. D. Screening for depression in elderly primary care patients. A comparison of the Center for Epidemiologic Studies-Depression Scale and the Geriatric Depression Scale. Arch Intern Med. 1997 Feb 24;157(4):449–454. [PubMed] [Google Scholar]
  14. Mayeux R., Sano M. Treatment of Alzheimer's disease. N Engl J Med. 1999 Nov 25;341(22):1670–1679. doi: 10.1056/NEJM199911253412207. [DOI] [PubMed] [Google Scholar]
  15. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  16. Mitnitski A. B., Graham J. E., Mogilner A. J., Rockwood K. The rate of decline in function in Alzheimer's disease and other dementias. J Gerontol A Biol Sci Med Sci. 1999 Feb;54(2):M65–M69. doi: 10.1093/gerona/54.2.m65. [DOI] [PubMed] [Google Scholar]
  17. Mohs R. C., Doody R. S., Morris J. C., Ieni J. R., Rogers S. L., Perdomo C. A., Pratt R. D., "312" Study Group A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001 Aug 14;57(3):481–488. doi: 10.1212/wnl.57.3.481. [DOI] [PubMed] [Google Scholar]
  18. Pfeffer R. I., Kurosaki T. T., Chance J. M., Filos S., Bates D. Use of the mental function index in older adults. Reliability, validity, and measurement of change over time. Am J Epidemiol. 1984 Dec;120(6):922–935. doi: 10.1093/oxfordjournals.aje.a113963. [DOI] [PubMed] [Google Scholar]
  19. Pfeffer R. I., Kurosaki T. T., Harrah C. H., Jr, Chance J. M., Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982 May;37(3):323–329. doi: 10.1093/geronj/37.3.323. [DOI] [PubMed] [Google Scholar]
  20. Pryse-Phillips W. Do we have drugs for dementia? No. Arch Neurol. 1999 Jun;56(6):735–737. doi: 10.1001/archneur.56.6.735-a. [DOI] [PubMed] [Google Scholar]
  21. Rockwood K., Joyce B., Stolee P. Use of goal attainment scaling in measuring clinically important change in cognitive rehabilitation patients. J Clin Epidemiol. 1997 May;50(5):581–588. doi: 10.1016/s0895-4356(97)00014-0. [DOI] [PubMed] [Google Scholar]
  22. Rockwood K., MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology. 2001 May;20(2):51–56. doi: 10.1159/000054761. [DOI] [PubMed] [Google Scholar]
  23. Rockwood K., Stadnyk K., Carver D., MacPherson K. M., Beanlands H. E., Powell C., Stolee P., Thomas V. S., Tonks R. S. A clinimetric evaluation of specialized geriatric care for rural dwelling, frail older people. J Am Geriatr Soc. 2000 Sep;48(9):1080–1085. doi: 10.1111/j.1532-5415.2000.tb04783.x. [DOI] [PubMed] [Google Scholar]
  24. Rockwood K., Stolee P., Fox R. A. Use of goal attainment scaling in measuring clinically important change in the frail elderly. J Clin Epidemiol. 1993 Oct;46(10):1113–1118. doi: 10.1016/0895-4356(93)90110-m. [DOI] [PubMed] [Google Scholar]
  25. Rockwood K., Stolee P., Howard K., Mallery L. Use of Goal Attainment Scaling to measure treatment effects in an anti-dementia drug trial. Neuroepidemiology. 1996;15(6):330–338. doi: 10.1159/000109923. [DOI] [PubMed] [Google Scholar]
  26. Rogers S. L., Farlow M. R., Doody R. S., Mohs R., Friedhoff L. T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan;50(1):136–145. doi: 10.1212/wnl.50.1.136. [DOI] [PubMed] [Google Scholar]
  27. Rogers S. L., Friedhoff L. T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia. 1996 Nov-Dec;7(6):293–303. doi: 10.1159/000106895. [DOI] [PubMed] [Google Scholar]
  28. Rosen W. G., Mohs R. C., Davis K. L. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 Nov;141(11):1356–1364. doi: 10.1176/ajp.141.11.1356. [DOI] [PubMed] [Google Scholar]
  29. Standish T. I., Molloy D. W., Bédard M., Layne E. C., Murray E. A., Strang D. Improved reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) compared with the Alzheimer's Disease Assessment Scale (ADAS). J Am Geriatr Soc. 1996 Jun;44(6):712–716. doi: 10.1111/j.1532-5415.1996.tb01838.x. [DOI] [PubMed] [Google Scholar]
  30. Stolee P., Rockwood K., Fox R. A., Streiner D. L. The use of goal attainment scaling in a geriatric care setting. J Am Geriatr Soc. 1992 Jun;40(6):574–578. doi: 10.1111/j.1532-5415.1992.tb02105.x. [DOI] [PubMed] [Google Scholar]
  31. Swanwick G. R., Lawlor B. A. Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease. Int J Geriatr Psychiatry. 1999 Apr;14(4):244–248. doi: 10.1002/(sici)1099-1166(199904)14:4<244::aid-gps917>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  32. Winblad B., Brodaty H., Gauthier S., Morris J. C., Orgogozo J. M., Rockwood K., Schneider L., Takeda M., Tariot P., Wilkinson D. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry. 2001 Jul;16(7):653–666. doi: 10.1002/gps.496. [DOI] [PubMed] [Google Scholar]
  33. Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wimo A., Wetterholm A. L., Zhang R., Haglund A., Subbiah P. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001 Aug 14;57(3):489–495. doi: 10.1212/wnl.57.3.489. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES